At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase 2 Study to Evaluate Safety and Efficacy of the Combination of SHR-1210 With Capecitabine + Oxaliplatin or Apatinib as First-line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
In Brief
A Phase 2 clinical trial evaluating SHR-1210, Capecitabine, and 2 other interventions for Gastric Cancer and GastroEsophageal Cancer. Completed, enrolled 67 participants across 1 site.
Detailed Summary
The purpose of this trial is to estimate overall response rate (ORR) of SHR-1210 combined with capecitabine and oxaliplatin or with apatinib as first-line treatment in subjects with locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Study Details
Timeline
Interventions
SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
1000 mg/m\^2 administered as continuous oral twice daily (BID) of each 3-week cycle.
130 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle.
375 mg administered as continuous oral once daily (QD) of each 3-week cycle.